|
|
Article: Alcon Receives Approval of RETAANE(R) Suspension in Australia.
- Article from:
- Business Wire
- Article date:
- December 12, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HUNENBERG, Switzerland -- Alcon, Inc. (NYSE:ACL) announced today that the Australian Therapeutic Goods Administration (TGA) has approved RETAANE(R) suspension (15mg anecortave acetate suspension) for the treatment of subfoveal choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD) where there is a classic component.
"We are pleased to gain approval of RETAANE(R) suspension in Australia for all lesions with a classic component because we believe RETAANE(R) suspension can provide retinal specialists with a unique new therapy to treat wet AMD. We will continue our efforts to gain approval of RETAANE(R) suspension in other ...